Ionis’ Tegsedi launches into head-to-head with Alnylam, but Pfizer’s waiting in the wings
admin 8th October 2018 Uncategorised 0It’s game on between Ionis and Alnylam in hATTR. Not only has Ionis’ affiliate Akcea priced its now FDA-approved Tegsedi the same as Alnylam’s Onpattro, it’s also exploring value-based deals with payers. And a potential third player, Pfizer, will only complicate the battle.
More: Ionis’ Tegsedi launches into head-to-head with Alnylam, but Pfizer’s waiting in the wings
Source: fierce